EQS-News: Marinomed Biotech AG seeks reorganisation through restructuring proceedings without self-administration

EQS-News: Marinomed Biotech AG / Key word(s): Insolvency
   Marinomed Biotech AG seeks reorganisation through restructuring
   proceedings without self-administration

   22.07.2026 / 14:48 CET/CEST
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

    Marinomed Biotech AG seeks reorganisation through restructuring
   proceedings without self-administration

     • Application for the opening of restructuring proceedings filed
     • Outstanding earn-out payments from Unither Pharmaceuticals and
       termination of negotiations by Unither.
     • Coordination with creditors intended to secure the Company’s
       sustainable continuation

    

   Korneuburg, Austria, July 22^nd, 2026 – Marinomed Biotech AG (VSE) has
   filed an application with the Regional Court of Korneuburg for the opening
   of restructuring proceedings without self-administration. The application
   was prompted by outstanding earn-out payments from Unither relating to the
   sale of the Carragelose business and Unither Pharmaceuticals’ termination
   of related negotiations. As a result, the court-approved restructuring
   plan dated 14 November 2024 can no longer be fulfilled, exposing the
   Company to the risk of insolvency. The “Carragelose” business was sold  in
   an asset deal, and the business operations were transferred in February
   2025. The purchase price for the “Carragelose” business comprises a fixed
   purchase price component of EUR 5 million as well as conditional earn-out
   payments. The earn-out payments are of central importance to Marinomed, as
   they were intended to finance a significant portion of the restructuring
   plan. To date, none of the agreed earn-out payments have been received by
   the Company. Marinomed takes the position that Unither failed to achieve
   the agreed targets due to culpable delays in concluding customer contracts
   and a change in its corporate strategy. The discussions with Unither have
   stopped without success, and no commercially viable agreement regarding
   the earn-out payments could be reached.

   The objective of the proceedings is to implement a restructuring plan and
   achieve the sustainable financial stabilisation of the Company. In
   addition to further restructuring measures, Marinomed intends to pursue
   the legal remedies available against Unither and realise the potential of
   its recently launched compounding business.

   The strained liquidity situation arose because, despite intensive efforts,
   no short-term agreement could be reached with Unither and because the
   conclusion of additional partnerships for Marinosolv products was delayed.
   As a result, significant milestone payments were not received.

   “To safeguard the financial stability of the Company, we have therefore
   decided to apply for restructuring proceedings. We believe that this
   offers the best opportunity to create a sustainable foundation for the
   continuation of the Company and the commercialisation of our innovative
   products. The situation with Unither has significantly restricted our
   business activities and financing options in recent months,” said Andreas
   Grassauer, CEO of Marinomed. “Applying for these proceedings is currently
   the only available option for the Company. It gives us the opportunity to
   improve the Company’s financial position while continuing to develop our
   assets. We are working hard to achieve a successful restart and preserve
   the value created for all stakeholders. We are grateful for the trust
   placed in us.”

   As part of the application, the Management Board of Marinomed Biotech AG
   will submit a proposed restructuring plan. The Company’s business
   operations are intended to continue throughout the restructuring
   proceedings.

   Marinomed Biotech AG generated revenue of approximately EUR 7.7 million in
   the 2025 financial year. Around 30 employees are currently employed at the
   Company’s site in Korneuburg. Liabilities amount to approximately EUR 27.9
   million, including claims from 2024 that have become enforceable again.

   Due to the current developments, Marinomed Biotech AG is postponing the
   publication of its 2026 half-year financial report, which was scheduled
   for 16 September 2026.

   Marinomed further announces that the existing contract for the provision
   of liquidity services (market making) with Raiffeisen Bank International
   has been terminated by the contractual partner with immediate effect. Due
   to the sudden cessation of market making, there may be a short-term
   decrease in liquidity for trading Marinomed Biotech AG shares and larger
   bid-ask spreads. The tradability of the shares on the respective stock
   exchanges remains fundamentally unaffected. The Management Board is
   working to agree on a successor market-making mandate promptly and to
   restore the usual liquidity in the trading of the shares.

   The Company will keep the public and all affected stakeholders informed of
   material developments on an ongoing basis. Further information is
   available on the Company’s website at [1]www.marinomed.com under
   “Investors & ESG”.

    

   About Marinomed Biotech AG

   Marinomed Biotech AG is an Austrian, science-based biotech company with a
   growing development pipeline. The Company develops innovative
   patent-protected products based on the Marinosolv® platform. The
   Marinosolv® technology improves the solubility and bioavailability of
   hardly soluble compounds and is used to develop new therapeutics for
   autoreactive immune disorders. The Company is headquartered in Korneuburg,
   Austria, and is listed on the Vienna Stock Exchange (VSE:MARI). For
   further information, please visit: [2]https://www.marinomed.com.

    

    

   For further inquiries contact:

   Marinomed Biotech AG         
   PR: Luca Horinek
   IR.: Tobias Meister
   T: +43 2262 90300 158
   E-Mail: [3][email protected]
   E-Mail: [4][email protected]

    

   Disclaimer

   The new shares and subscription rights have not been and will not be
   registered under foreign securities laws – in particular under the U.S.
   Securities Act of 1933, as amended ("Securities Act") – with foreign
   securities authorities and may not be offered or sold, in particular in
   the United States of America ("US"), without registration or an exemption
   from the registration requirements under the Securities Act. This
   communication is not intended for distribution to or within the US and may
   not be distributed or forwarded to publications with general circulation
   in the US. This communication constitutes neither an offer to sell nor an
   invitation to subscribe for or purchase securities in any jurisdiction in
   which such an offer or such an invitation would be unlawful.

   ══════════════════════════════════════════════════════════════════════════

   22.07.2026 CET/CEST This Corporate News was distributed by [5]EQS Group

   View original content: [6]EQS News

   ══════════════════════════════════════════════════════════════════════════

   Language:    English
   Company:     Marinomed Biotech AG
                Hovengasse 25
                2100 Korneuburg
                Austria
   Phone:       +43 2262 90300
   E-mail:      [email protected]
   Internet:    www.marinomed.com
   ISIN:        ATMARINOMED6
   WKN:         A2N9MM
   Listed:      Regulated Unofficial Market in Dusseldorf, Frankfurt, Munich,
                Stuttgart, Tradegate BSX; Vienna Stock Exchange (Official
                Market)
   LEI Code:    529900GN3B1EN80XF405
   EQS News ID: 2370070


    
   End of News EQS News Service


   2370070  22.07.2026 CET/CEST

   https://nwr.eqs-cockpit.com/fncls2.ssx?application_id=2370070&application_name=news&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf

References

   Visible links
   1. https://nwr.eqs-cockpit.com/fncls2.ssx?fn=redirect&url=8ca14f41cb68edc7b558d3d7821b7c34&application_id=2370070&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   2. https://nwr.eqs-cockpit.com/fncls2.ssx?fn=redirect&url=b364e041c58da1aeff9758a10a9b0152&application_id=2370070&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   3. mailto:[email protected]
   4. mailto:[email protected]
   5. https://nwr.eqs-cockpit.com/fncls2.ssx?fn=redirect&url=f5d50dc7e8798b6eb177f7955e598e60&application_id=2370070&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news
   6. https://nwr.eqs-cockpit.com/fncls2.ssx?fn=redirect&url=bdd8c1874d120131a4e09f0e0148121d&application_id=2370070&site_id=apa_ots_austria~~~18b544d0-9c71-4160-bd95-cc8b9aff9fbf&application_name=news

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT |

print